ARIZ (Pronounced “ARISE”) uses nano-technology based systems to deliver therapeutics to individually target and destroy cancer cells, without harming normal cells. ARIZ’s therapeutic targets are a family of gene targets known as the PRDMs (Positive Regulatory Domain-containing Methyltransferase). The 16-member PRDM family of genes and proteins are well recognized as genetic drivers of early cancer.
The lead drug candidate, ARIZ-047, has been tested in preclinical models of cancer, and has been shown to be highly effective in killing cancer cells (>90% cell killing in vitro), as well as achieving a 80% reduction in tumor growth in an in vivo mouse xenograft model. Currently in advanced preclinical development for treating lung and other solid tumors, ARIZ-047 is the first compound demonstrating the ability of this powerful platform to rapidly identify first-in-class and best-in-class PRDM drug candidates. A robust portfolio of 7 drug candidates are targeting the most common forms of cancer.
Website: https://arizbio.com